NCT01843894View on ClinicalTrials.gov

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Dry Eye
Interventions
BIOLOGICAL

RU-101

Recombinant human serum albumin

Trial Locations (1)

22655-5342

Virginia Eye Consultants, Norfolk

All Listed Sponsors
lead

R-Tech Ueno, Ltd.

INDUSTRY

NCT01843894 - A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye | Biotech Hunter | Biotech Hunter